Analyst Price Targets — AZN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 10, 2025 11:14 am | — | HSBC | $216.00 | $179.64 | TheFly | AstraZeneca price target raised to $108 from $95 at HSBC |
| December 3, 2025 11:30 am | — | Morgan Stanley | $206.00 | $180.34 | TheFly | AstraZeneca price target raised to $103 from $93 at Morgan Stanley |
| July 9, 2025 7:38 pm | Luisa Hector | Berenberg Bank | $194.00 | $141.64 | TheFly | AstraZeneca price target raised to $97 from $93 at Berenberg |
| November 13, 2024 1:13 pm | Etzer Darout | BMO Capital | $176.00 | $162.38 | StreetInsider | AstraZeneca (AZN) PT Lowered to $88 at BMO Capital |
| September 11, 2024 8:18 am | Etzer Darout | BMO Capital | $178.00 | $159.88 | StreetInsider | BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN) |
| May 30, 2024 7:07 am | John Eade | Argus Research | $170.00 | $153.68 | StreetInsider | AstraZeneca (AZN) PT Raised to $85 at Argus |
| May 28, 2024 9:20 am | Etzer Darout | BMO Capital | $164.00 | $153.48 | StreetInsider | BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN) |
| July 12, 2023 8:44 am | Andrew Berens | Leerink Partners | $158.00 | $129.72 | Benzinga | These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts |
| January 5, 2023 7:01 am | — | BMO Capital | $164.00 | $139.00 | Benzinga | BMO Capital Initiates Coverage On AstraZeneca with Outperform Rating, Announces Price Target of $82 |
| November 11, 2022 3:58 am | — | Leerink Partners | $156.00 | $130.18 | Benzinga | SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $78 |
Latest News for AZN
AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.
AstraZeneca reports positive SANOVO data, showing Tagrisso plus Orpathys improved PFS in first-line EGFR-mutated NSCLC.
AstraZeneca (AZN), the global oncology and biopharmaceutical powerhouse, delivered another Phase 3 victory Tuesday, with its stock priced at $161.62. Tagrisso c
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY® (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through this agreement, AstraZeneca has acquired worldwide rights to develop and commercialize ZEGFROVY.…
AstraZeneca said on Tuesday that a Chinese late-stage trial of a combination of its cancer drugs Tagrisso and Orpathys significantly improved progression-free survival when given as a first-line treatment for a type of lung cancer.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.